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Abstract 
Review on Renal cell carcinoma with 
t(X;1)(p11;q21) PRCC/TFE3, with data on clinics, 
and the genes involve 
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Classification 
Xp11 translocation renal cell carcinoma (RCCs) 
harbor gene fusions involving TFE3 transcription 
factor.  The The t(6;11) RCCs harbor a specific 
MALAT1 (Alpha) - TFEB gene fusion. TFEB and 
TFE3 belong to the same MiT subfamily of 
transcription factors.  
Because of similarities at the clinical, morphologic, 
immunohistochemical, and genetic levels, the Xp11 
translocation RCCs and t(6;11) RCCs are currently 
grouped together under the category of  MiT family 
translocation renal cell carcinoma.) 
Clinics and pathology 
Disease 
Renal cell carcinoma. 
Phenotype / cell stem origin 
t(X;1) (p11;q21) PRCC/TFE3 is found in Xp11 
translocation renal cell carcinoma. 
Figure 1 t(X;1)(p11;q21) (G banding) - Courtesy Francois Desangles. 
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Epidemiology 
Approximately 40 reported cases, median age 20 
yrs (range 2-69); sex ratio: 17M/20F. A subset of 
cases has been associated with prior exposure to 
cytotoxic chemotherapy. 
Pathology 
PRCC  frequently have papillary architecture with 
clear cytoplasm and abundant psammoma bodies. 








TFE3 and PRCC/TFE3 
Additional anomalies 
+17. 
Genes involved and 
proteins 
TFE3 (transcription factor E3) 
Location Xp11.23 
Protein 
Transcription factor; binds to the immunoglobulin 
enhancer. 
PRCC (papillary renal cell carcinoma) 
Location 1q23.1 
Protein 
491aa; widely expressed; proline rich. 




5' TFE3 - 3' PRCC and 5' PRCC - 3' TFE3 
Detection 
positional cloning; screening in a tumor cDNA 
library and hybridization with TFE3 
Fusion Protein 
Description 
PRCC/TFE3 fusion protein includes the  
 
transcription activating, helix-loop-helix and 
leucine-zipper domains of TFE3; the TFE3/PRCC 
fusion protein (513 amino acids) is also expressed. 
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